MarketingMedicalPolicy,Access,Value, andEvidenceConsultingData,Technology,and Media
murmuration of birds
Previous
Next

thought leadership

Phase 2 trials: A pivotal moment for launch success

Hassan Choudhury, Head, Early-Stage Strategy; Genevieve Ball, Head, Go-to-Market Strategy; and Gary Choy, Senior Consultant | 9/25/2023

In accelerated launch timelines and highly competitive oncology landscapes, a successful launch requires a different approach. Biopharmaceutical manufacturers are rethinking Phase 2 trials to infuse the clinical strategy with commercial thinking to drive value for stakeholders across the product life cycle.

In 2022, more than 700 oncology products were in the late stages of the development pipeline—an increase of 60% over the previous decade. The rise in competition—fueled in part by scientific advancements and treatments targeting smaller patient populations—has created a complex environment for stakeholders to navigate as they work toward improving patient outcomes. These stakeholders include policymakers, healthcare professionals, and patients, along with regulators and payers, with nuanced needs to be considered from an early stage to ensure success later on.

Launch challenges are heightened in accelerated environments, where timelines for new oncology products are shorter than in traditional trial protocols and regulatory bodies are putting pressure on biopharmaceutical organizations to improve the data available at the time of accelerated approval.

To be successful, biopharmaceutical manufacturers are rethinking their approach to early-phase clinical trials, applying a commercial lens to maximize value across the product life cycle, including exploring how technology could help improve product development.

Competing in a constantly evolving oncology landscape

The crowded, rapidly evolving, and personalized oncology space creates challenges and opportunities for developers of new therapeutics.

As a result, manufacturers are looking for innovative approaches for speed to market while also being mindful of commercial value and competitive differentiation as the market evolves.

Key considerations affecting the complex oncology landscape include:

  • Greater complexity within a crowded marketplace
  • An increased emphasis on highly targeted patient subpopulations
  • More sophisticated study design
  • Increasingly personalized therapies
  • A continuously evolving regulatory landscape

Each trend requires a rethink of the clinical trials to deliver evidence beyond the scientific benefits, ensuring value is crystalized for a range of stakeholders so they are better equipped to make critical healthcare decisions.

 

Fill out the form below to read the full article in our Oncology eBook.

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Avalere Health website, such as the pages you visit.

For more information, check the cookie statement

32E8261E-A569-4B66-ACC6-3CB772DDEDEE

Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use.

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on avalerehealth.com, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on Avalerehealth.com.

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.